Alzheimer Disease Markets, 2026


Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com

SOURCE Research and Markets

DUBLIN, September 19, 2017 /PRNewswire/ —

The “Alzheimer Disease – New Drugs, Markets and Companies” report from Jain PharmaBiotech has been added to Research and Markets’ offering.

Research and Markets Logo

The current management of Alzheimer’s disease is reviewed and it involves a multidisciplinary approach. Acetylcholinesterase inhibitors are mostly a symptomatic treatment but some claims are made about a neuroprotective effect. Currently the only approved neuroprotective therapy in is memantine. Management of these patients also require neuroleptics for aggressive behavior and antidepressants. There is an emphasis on early detection at the stage of mild cognitive impairment and early institution of neuroprotective measures. The value of mental exercise in delaying the onset of Alzheimer’s disease is being recognized.

Research in Alzheimer’s disease still aims at elucidating the basic pathomechanisms. Animal models are important for research, particularly in testing some of the potential therapeutic approaches. There is considerable research in progress at the various centers, some of which is funded by the National Institute of Aging of the National Institutes of Health.

Over 300 different compounds are at various stages of development for the treatment of Alzheimer’s disease. These are classified and described. There are non-pharmacological approaches such as vagal nerve stimulation and cerebrospinal fluid shunting, which are in clinical trials. As of April 2017, the number of clinical trials of AD on US Government clinical trials web site was over 1900. Selected 234 clinical trials are listed, of which 165 are still in progress and 69 were discontinued for various reasons.

Alzheimer’s disease market in the seven major markets is analyzed for the year 2016. Several new therapies are expected to be in the market and the shares of various types of approaches are estimated for the future up to the year 2026. As a background to the markets, pharmacoeconomic aspects of care of Alzheimer disease patients and patterns of practice are reviewed in the seven major markets.

Profiles of 144 companies involved in developing diagnostics and therapeutics for Alzheimer’s disease are presented along with 92 collaborations. The bibliography contains over 910 publications that are cited in the report.The report is supplemented with 47 tables and 22 figures.

Key Topics Covered:

1. Clinical Features, Epidemiology and Pathology

2. Diagnostic Procedures for Alzheimer Disease

3. Management of Alzheimer Disease

4. Research in Alzheimer Disease

5. Drug Discovery & Development for Alzheimer Disease

6. Markets & Finances of AD Care

7. Companies

8. References

For more information about this report visit https://www.researchandmarkets.com/research/f7xz3g/alzheimer_disease

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

View original content:http://www.prnewswire.com/news-releases/alzheimer-disease-markets-2026-new-drugs-markets-and-companies—profiles-of-144-companies-with-92-collaborations-300521913.html

©2017 PR Newswire. All Rights Reserved.



Read more

Leave A Comment

Your email address will not be published. Required fields are marked *